Imakin 100 mg (Tablet)
Unit Price: ৳ 100.00 (3 x 10: ৳ 3,000.00)
Strip Price: ৳ 1,000.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Imatinib mesylate |
| Company | Ziska pharmaceuticals ltd |
| Also available as |
Indications
- Treatment of chronic myeloid leukemia (CML) in chronic phase
- Treatment of CML in blast crisis or accelerated phase
- Treatment of acute lymphoblastic leukemia
- Treatment of myeloproliferative diseases associated with PDGFR gene rearrangements
- Treatment of aggressive systemic mastocytosis
- Treatment of hypereosinophilic syndrome
- Treatment of dermatofibrosarcoma protuberans
- Treatment of gastrointestinal stromal tumors (GIST)
- Adjuvant treatment following complete resection of GIST
- Dosage for adults with CML in chronic phase
- Dosage for adults with CML in accelerated or blast phase
- Dosage for pediatric patients with CML in chronic phase
- Dosage for adults and pediatric patients with acute lymphoblastic leukemia
- Dosage for patients with myelodysplastic/myeloproliferative diseases
- Dosage for patients with aggressive systemic mastocytosis
- Dosage for patients with hypereosinophilic syndrome
- Dosage for patients with dermatofibrosarcoma protuberans
- Dosage for patients with GIST and adjuvant treatment
- Interaction with agents inducing CYP3A metabolism
- Interaction with agents inhibiting CYP3A metabolism
- Interaction with drugs metabolized by CYP3A4
- Interaction with drugs metabolized by CYP2D6
- Side effects including fluid retention, hematologic toxicity, congestive heart failure, hepatotoxicity, hemorrhage
- Pregnancy precautions and contraception advice
- Breastfeeding advice
- Fertility considerations
- Warnings for edema and fluid retention
- Warnings for cytopenias
- Warnings for congestive heart failure
- Warnings for hepatotoxicity
- Warnings for hemorrhage
- Warnings for cardiac shock and left ventricular dysfunction
- Warnings for dermatologic reactions
- Warnings for hypothyroidism
- Warnings for fetal harm
- Warnings for growth retardation in children
- Warnings for tumor lysis syndrome
- Warnings for impairments related to driving and machinery use
- Warnings for renal toxicity
- Overdose effects in adult population
- Overdose effects in pediatric population
- Therapeutic class as targeted cancer therapy
- Storage conditions
Pharmacology
- Inhibition of Bcr-Abl tyrosine kinase
- Inhibition of receptor tyrosine kinases: Kit, DDR1, DDR2, CSF-1R, PDGFR-alpha and beta
- Absorption and distribution characteristics
- Metabolism by CYP3A4 and other cytochrome P450 enzymes
- Active metabolite formation
- Plasma protein binding
- Excretion through feces and urine
- Elimination half-lives of Imatinib and its major active metabolite
Dosage & Administration
- Recommended daily dosages for different conditions
- Instructions for administration with food and water
- Instructions for patients who have difficulty swallowing
- Special dosing considerations for patients with hepatic impairment
Interaction
- Impact of CYP3A4 inducers on imatinib exposure
- Impact of CYP3A4 inhibitors on imatinib exposure
- Effect on drugs metabolized by CYP3A4
- Effect on drugs metabolized by CYP2D6
Side Effects
- Description of serious adverse reactions
- Information on specific adverse effects
Pregnancy & Lactation
- Contraception advice for women of childbearing potential
- Data on use during pregnancy
- Potential risk to the fetus
- Information on breastfeeding
- Fertility considerations
Precautions & Warnings
- Edema and fluid retention precautions
- Cytopenias precautions
- Congestive heart failure precautions
- Hepatotoxicity precautions
- Hemorrhage precautions
- Cardiogenic shock and left ventricular dysfunction warnings
- Dermatologic reactions warnings
- Hypothyroidism warnings
- Fetal harm warnings
- Growth retardation warnings
- Tumor lysis syndrome warnings
- Impairments related to driving and machinery use warnings
- Renal toxicity warnings
Overdose Effects
- Reported events in adult population at different dose ranges
- Reported events in pediatric population at different dose ranges
Therapeutic Class
- Targeted Cancer Therapy, Tyrosine Kinase Inhibitor
Storage Conditions
- Storage temperature and precautions